The BMS sac of the Pharmaceutical Rapid Reading Society was clinically failed in the second phase of the innovative IL-12 therapy UBX0101.

August 18, 2020 / Medical Information At a Glance: The 2020 National Health Insurance Drug Catalog Adjustment Work Programme was officially announced; Gilead and Tango expand tumor strategy cooperation; assisted treatment of small cell lung cancer G1 CDK4/6 inhibitors by FDA priority review; Corning Jerry PD-L1/CTLA-4 double anti-approved clinical ... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief August 17 22 new confirmed cases No new suspected cases August 17 0-24 hours, 31 provinces (autonomous regions, municipalities directly under the Central Government) and Xinjiang Production and Construction Corps reported 22 new confirmed cases, all imported cases abroad (Shanghai 14 cases, Jiangsu 3 cases, Tianjin 2 cases, Shaanxi 2 cases, Guangdong 1 case);
(National Health And Wellness Commission) "2020 National Health Insurance Drug Catalog Adjustment Work Programme" officially announced August 3-10, the State Health Insurance Administration on the "2020 National Health Insurance Drug Catalog Adjustment Work Programme (Draft for Comments)" to the public for comments.
17th, the 2020 National Health Insurance Drug Catalog Adjustment Work Programme and the 2020 National Health Insurance Drug Catalog Adjustment Reporting Guidelines were officially announced.
(National Health Insurance Administration) State Drug Administration issued a document: strict inspection of practicing pharmacists certified by the State Drug Administration issued a document on the 17th, publicly solicited "on the regulation of drug retail enterprises equipped with the use of practicing pharmacists notice (draft for comments)" opinions.
it refers to further regulating the requirements of pharmaceutical technicians in pharmaceutical retail enterprises, continuously promoting the use of licensed pharmacists, and actively playing the important role of practicing pharmacists in ensuring the safety and effectiveness of public drug use.
(State Drug Administration) Health Insurance Bureau news repayment policy came on the 17th, Henan Provincial Health Insurance Bureau issued "Henan Province to carry out centralized procurement and use of pharmaceutical medical supplies implementation plan", the content of which indicates that will further reduce the price of pharmaceutical supplies;
implementation, the scope of procurement will be gradually expanded, in accordance with the "provincial organizations, alliance procurement, platform operations" of the overall thinking, to ensure quality, ensure supply, ensure use, ensure repayment.
(Henan Provincial Health Insurance Bureau) Part 2 is worth more than $6 billion! Gilead and Tango Expanded Oncology Strategy Cooperation 17 local time, Gilead and Tango Therapeutics announced the expansion of strategic cooperation to identify, develop and commercialize innovative immunoescapammunity-targeted therapies for cancer patients, with a portfolio value of up to $6 billion.
(Sina Pharmaceutical News) $475 million upfront payment, BMS has been announced by innovative IL-12 therapy BMS and Dragonfly, the two sides have reached a cooperation agreement, BMS will be developed by Dragonfly's white melein-12 (IL-12) in the study of immunotherapy DF6002 global exclusive license.
agreement, BMS will be responsible for the global development and any subsequent roll-out of DF6002 and its related products.
Dragonfly will receive an upfront payment of $475 million and will be eligible for subsequent milestone payments, as well as a share of future product sales.
(Drug Mingkangde) Part 3 Drug News Unity's main product UBX0101 Phase II Clinical Failure Unity announced that its main product UBX0101 failed to beat the placebo in a 183-person osteoarthritis Phase II clinical trial.
the trial's first-level endpoint was a 12-week WOMMAC-A score, and the results showed not only that UBX0101 was no different from a placebo, but also did not show a meaningful effect relationship, and in fact only the lowest dose showed a certain trend in efficacy.
(U.S. and Chinese medicine source) GNI Group F351 (hydroxyne) treatment of hepatitis B-related hepatic fibrosis China Phase II research successful GNI Group recently announced that the evaluation of F351 (hydronicone, Hydronidone) treatment of hepatitis B-related liver fibrosis in a Chinese Phase II clinical study in the main endpoint analysis obtained positive results.
was a randomized, double-blind, placebo-controlled, multi-center, dose-incremental study that evaluated the efficacy and safety of F351 in treating liver fibrosis in patients with chronic hepatitis B in China.
(Sina Pharmaceutical News) Tianmai bio-recombinant human insulin intestinal capsule (ORMD-0801) started Phase III clinical recently, Hefei Tianmai Bio and Israel Oramed Co., Ltd. jointly developed the new oral insulin drug ORMD-0801 in China to start Phase III clinical, oral insulin is a big step closer to the market.
of this study was to assess the effectiveness of co-recombinant human insulin intestinal capsule therapy in subjects with type 2 diabetes who had poor blood sugar control of oral hypoglycemic drugs.
(Insight Database) pioneered the pharmaceutical industry "Forrethan" to start Phase II clinical 17, to open up the pharmaceutical industry 1 new drug, Frietha Ennin to start Phase II clinical, the drug is its own research and development of an AR antagonist, used to treat adult male androgen baldness in China.
(Insight Database) auxiliary treatment of small cell lung cancer G1 CDK4/6 inhibitors by the FDA priority review local time on the 17th, G1 announced that the FDA has accepted its Trilaciclib, as a chemotherapy treatment of small cell lung cancer patients bone marrow protection therapy application, and give priority review, prescription drug user fee law target date of February 15, 2021.
(Xinhua) -- The FDA has accepted applications for new drugs for relugolix compound tablets, Myovant announced recently, and the FDA has accepted applications for new drugs for relugolix compound tablets, which are taken oral once a day for women to treat moderate to severe symptoms associated with uterine fibroids.
two most common symptoms of uterine fibroids are multiple months and pain.
(Bio Valley) Corning Jerry PD-L1/CTLA-4 dual-anti-approved clinical CDE latest publicity, Corning Jerry's recombinant humanized PD-L1/CTLA-4 dual-specific monometric antibody Fc fusion protein injection obtained a clinical trial implied license to develop an adaptation: comodyl sulfonate donafini tablets for the treatment of advanced digestive tract tumors.
according to Corning Jerry's official information, this is a research and development code-named KN046 in the study of new drugs.
(CDE) nine-year pharmaceutical acautamine tablets by the "drug clinical trial approval notice" nine-year pharmaceutical announcement, the company recently received the State Drug Administration issued the "drug clinical trial approval notice", after the completion of the relevant preparations will be carried out clinical trial research.
hydrochloride is a new selective acetylcholinesterase inhibitor, which can improve the symptoms caused by functional indigestion, such as fullness, upper bloating and early satiety after meals.
(Nine-Year Pharmaceutical Announcement) The company recently received the "Drug Clinical Trial Approval Notice" issued by the State Drug Administration regarding liraglutide injections, the clinical trial approval notice said in a statement.
liraglutide is an aamideized GLP-1 subjector atrial agent that promotes insulin secretion, simulates the body's own endocrine, protects islet beta cells, and delays stomach emptying to reduce appetite.
(Shuangyi Pharmaceutical Announcement) Jiangsu Jiayi Pharmaceutical "Apixaban Tablets" over-evaluation of the Official Website of the State Drug Administration shows that Jiangsu Jiayi Pharmaceuticals "Apixaban Tablets" was approved, according to the new registration classification 4 categories were approved as if through the consistent evaluation.
Apixaban is a reversible, highly selective Xa factor inhibitor, a new oral anticoagulant drug suitable for adult patients with hip or knee replacement surgery to prevent venous thromboembolism events.
(Insight Database) Division Tyri iodized salga alcohol injection is about to be approved recently, Stai Li according to the imitation of the 4 categories of reported iodized keshaol injection registration status changed to "in the approval", is expected to be approved in recent days and as reviewed.
iodized kesalol is suitable for cardiovascular angiogenesic, cerebrovascular, excretional urinary tract angiitis and computer fault scanning in adults, allowing abnormal structures or lesions to develop to distinguish between healthy tissues and pathological tissues.
(Mienet)